The IKK NF-κB system: a treasure trove for drug development

Nuclear factor-κB (NF-κB)/Rel transcription factors have been suspected since their discovery to play a pivotal role in chronic and acute inflammatory diseases. It now seems that aberrant regulation of NF-κB could also underlie autoimmune diseases and different types of cancer. Recently, NF-κB and the signalling pathways that regulate its activity have become a focal point for intense drug discovery and development efforts. Given the large number of major ailments in which aberrant regulation of NF-κB has been observed or is suspected, such efforts seem well justified. This review will discuss recent progress in the development of drugs that inhibit NF-κB activation, and consider their potential applications in inflammatory and autoimmune diseases, as well as cancer.

[1]  M. Neurath,et al.  Cytokine Gene Transcription By NF‐κB Family Members in Patients with Inflammatory Bowel Disease , 1998 .

[2]  Takahiro Doi,et al.  NF‐κB inhibits TNF‐induced accumulation of ROS that mediate prolonged MAPK activation and necrotic cell death , 2003, The EMBO journal.

[3]  J. Minna,et al.  Sulindac Enhances Tumor Necrosis Factor-α-mediated Apoptosis of Lung Cancer Cell Lines by Inhibition of Nuclear Factor-κB , 2002 .

[4]  Hans Clevers,et al.  Activation of β-Catenin-Tcf Signaling in Colon Cancer by Mutations in β-Catenin or APC , 1997, Science.

[5]  T. Lawrence,et al.  Possible new role for NF-κB in the resolution of inflammation , 2001, Nature Medicine.

[6]  A. Israël.  Signal transduction: A regulator branches out , 2003, Nature.

[7]  A. Ciechanover,et al.  Stimulation-dependent I kappa B alpha phosphorylation marks the NF-kappa B inhibitor for degradation via the ubiquitin-proteasome pathway. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Brian D. Strahl,et al.  A nucleosomal function for IκB kinase-α in NF-κB-dependent gene expression , 2003, Nature.

[9]  D. Green,et al.  The Lymphotoxin-β Receptor Induces Different Patterns of Gene Expression via Two NF-κB Pathways , 2002 .

[10]  G. Bren,et al.  RelB Cellular Regulation and Transcriptional Activity Are Regulated by p100* , 2002, The Journal of Biological Chemistry.

[11]  N. Munshi,et al.  Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. , 2002, Blood.

[12]  安井 寛.  Combination of tumor necrosis factor-α with sulindac augments its apoptotic potential and suppresses tumor growth of human carcinoma cells in nude mice , 2004 .

[13]  B. Aggarwal,et al.  Thalidomide Suppresses NF-κB Activation Induced by TNF and H2O2, But Not That Activated by Ceramide, Lipopolysaccharides, or Phorbol Ester1 , 2002, The Journal of Immunology.

[14]  M. Karin,et al.  Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. , 1997, The New England journal of medicine.

[15]  R. Gaynor,et al.  Histone H3 phosphorylation by IKK-α is critical for cytokine-induced gene expression , 2003, Nature.

[16]  M. Kitagawa,et al.  An F‐box protein, FWD1, mediates ubiquitin‐dependent proteolysis of β‐catenin , 1999, The EMBO journal.

[17]  T. Deerinck,et al.  Abnormal Morphogenesis But Intact IKK Activation in Mice Lacking the IKKα Subunit of IκB Kinase , 1999 .

[18]  M. Kitagawa,et al.  Evidence that reactive oxygen species do not mediate NF‐κB activation , 2003 .

[19]  Jen-kun Lin,et al.  Suppression of TNFα‐mediated NFκb activity by myricetin and other flavonoids through downregulating the activity of IKK in ECV304 cells , 1999 .

[20]  R. Gaynor,et al.  Sulindac Inhibits Activation of the NF-κB Pathway* , 1999, The Journal of Biological Chemistry.

[21]  M. Karin,et al.  IKKα controls formation of the epidermis independently of NF-κB , 2001, Nature.

[22]  E. Stadtman,et al.  Protein Oxidation in Aging, Disease, and Oxidative Stress* , 1997, The Journal of Biological Chemistry.

[23]  G. Natoli,et al.  Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase , 2000, Nature.

[24]  T. Skov,et al.  CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo. , 1999, Cancer research.

[25]  Burkhard Haefner,et al.  NF-kappa B: arresting a major culprit in cancer. , 2002, Drug discovery today.

[26]  M J May,et al.  NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. , 1998, Annual review of immunology.

[27]  R. Gaynor,et al.  The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β , 1998, Nature.

[28]  S. Ghosh,et al.  Inhibition of NF-kappa B by sodium salicylate and aspirin. , 1994, Science.

[29]  E. Zandi,et al.  IKK-γ is an essential regulatory subunit of the IκB kinase complex , 1998, Nature.

[30]  R. Larsson,et al.  The combination of the antitumoural pyridyl cyanoguanidine CHS 828 and etoposide in vitro–from cytotoxic synergy to complete inhibition of apoptosis , 2002, British journal of pharmacology.

[31]  C. Glass,et al.  15-Deoxy-Δ12,14-prostaglandin J2 inhibits multiple steps in the NF-κB signaling pathway , 2000 .

[32]  A. Bowie,et al.  Vitamin C Inhibits NF-κB Activation by TNF Via the Activation of p38 Mitogen-Activated Protein Kinase1 , 2000, The Journal of Immunology.

[33]  W. Sandborn,et al.  Inhibition of Interleukin-1-stimulated NF-κB RelA/p65 Phosphorylation by Mesalamine Is Accompanied by Decreased Transcriptional Activity* , 1999, The Journal of Biological Chemistry.

[34]  L. Binderup,et al.  Novel cyanoguanidines with potent oral antitumour activity , 1997 .

[35]  E. Schmidt,et al.  IKKα Provides an Essential Link between RANK Signaling and Cyclin D1 Expression during Mammary Gland Development , 2001, Cell.

[36]  J. Christman,et al.  In vivo antioxidant treatment suppresses nuclear factor-kappa B activation and neutrophilic lung inflammation. , 1996, Journal of immunology.

[37]  M. Yao,et al.  A Selective IKK-2 Inhibitor Blocks NF-κB-dependent Gene Expression in Interleukin-1β-stimulated Synovial Fibroblasts* , 2003, Journal of Biological Chemistry.

[38]  T. Niki,et al.  Discovery of novel and selective IKK-beta serine-threonine protein kinase inhibitors. Part 1. , 2003, Bioorganic & medicinal chemistry letters.

[39]  A. Dalgleish,et al.  Thalidomide analogs as emerging anti-cancer drugs , 2003, Anti-cancer drugs.

[40]  Inder M. Verma,et al.  Severe Liver Degeneration in Mice Lacking the IκB Kinase 2 Gene , 1999 .

[41]  Michael Karin,et al.  NF-κB at the crossroads of life and death , 2002, Nature Immunology.

[42]  S. Ghosh,et al.  Selective inhibition of NF-κB activation by a peptide that blocks the interaction of NEMO with the IκB kinase complex , 2000 .

[43]  T. Deerinck,et al.  The IKKβ Subunit of IκB Kinase (IKK) is Essential for Nuclear Factor κB Activation and Prevention of Apoptosis , 1999, The Journal of experimental medicine.

[44]  D. Golde,et al.  Vitamin C suppresses TNF alpha-induced NF kappa B activation by inhibiting I kappa B alpha phosphorylation. , 2002, Biochemistry.

[45]  H. Lenz.  Clinical update: proteasome inhibitors in solid tumors. , 2003, Cancer treatment reviews.

[46]  M. Goldman,et al.  Structure–Activity Relationship Studies of Ethyl 2-[(3-Methyl-2,5-dioxo(3-pyrrolinyl))amino]-4-(trifluoromethyl)pyrimidine-5-carboxylate: An Inhibitor of AP-1 and NF-κB Mediated Gene Expression , 2002 .

[47]  D. Gilroy,et al.  Inducible cyclooxygenase may have anti-inflammatory properties , 1999, Nature Medicine.

[48]  D. Polk,et al.  Aminosalicylic Acid Inhibits IκB Kinase α Phosphorylation of IκBα in Mouse Intestinal Epithelial Cells* , 1999, The Journal of Biological Chemistry.

[49]  Paul Polakis,et al.  Stabilization of β-Catenin by Genetic Defects in Melanoma Cell Lines , 1997, Science.

[50]  F. Luscinskas,et al.  Salicylates inhibit I kappa B-alpha phosphorylation, endothelial-leukocyte adhesion molecule expression, and neutrophil transmigration. , 1996, Journal of immunology.

[51]  Stephen J. Elledge,et al.  The SCFβ-TRCP–ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IκBα and β-catenin and stimulates IκBα ubiquitination in vitro , 1999 .

[52]  Murata Toshiki.  Discovery of Novel and Selective IKK-β Serine Threonine Protein Kinase Inhibitors. Part 1. , 2003 .

[53]  N. Munshi,et al.  NF-κB as a Therapeutic Target in Multiple Myeloma* , 2002, The Journal of Biological Chemistry.

[54]  A. Baldwin,et al.  Inhibition of NF-κB Activity by Thalidomide through Suppression of IκB Kinase Activity* , 2001, The Journal of Biological Chemistry.

[55]  Michael Karin,et al.  Activation by IKKα of a Second, Evolutionary Conserved, NF-κB Signaling Pathway , 2001, Science.

[56]  M. Karin,et al.  The two faces of IKK and NF-κB inhibition: prevention of systemic inflammation but increased local injury following intestinal ischemia-reperfusion , 2003, Nature Medicine.

[57]  K. McIntyre,et al.  A highly selective inhibitor of I kappa B kinase, BMS-345541, blocks both joint inflammation and destruction in collagen-induced arthritis in mice. , 2003, Arthritis and rheumatism.

[58]  D. White,et al.  Rel/NF-kappaB/IkappaB proteins and cancer. , 1996, Oncogene.

[59]  A. Baldwin,et al.  Chemopreventive properties of trans-resveratrol are associated with inhibition of activation of the IkappaB kinase. , 2000, Cancer research.

[60]  J. Adams,et al.  Novel IKK inhibitors: β-carbolines , 2003 .

[61]  R. Surabhi,et al.  TAK1 is Critical for IκB Kinase-mediated Activation of the NF-κB Pathway , 2003 .

[62]  James R. Burke,et al.  BMS-345541 Is a Highly Selective Inhibitor of IκB Kinase That Binds at an Allosteric Site of the Enzyme and Blocks NF-κB-dependent Transcription in Mice* , 2003, The Journal of Biological Chemistry.

[63]  V. Godfrey,et al.  Female mice heterozygous for IKK gamma/NEMO deficiencies develop a dermatopathy similar to the human X-linked disorder incontinentia pigmenti. , 2000, Molecular cell.

[64]  Burkhard Haefner,et al.  NF-κB: arresting a major culprit in cancer , 2002 .

[65]  R. Schmid,et al.  Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. , 1998, The Journal of clinical investigation.

[66]  M. Karin,et al.  Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. , 2000, Annual review of immunology.

[67]  D. Straus.  15-deoxy Δ^ -PGJ2 inhibits multiple steps in the NF-kappaB signaling pathway , 2000 .

[68]  Christopher K. Glass,et al.  The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation , 1998, Nature.

[69]  Y. Xiong,et al.  HOS, a human homolog of Slimb, forms an SCF complex with Skp1 and Cullin1 and targets the phosphorylation-dependent degradation of IκB and β-catenin , 1999, Oncogene.

[70]  Céline Gélinas,et al.  Rel/NF-?B and I?B factors in oncogenesis , 1997 .

[71]  E. Harhaj,et al.  Retroviral oncoprotein Tax induces processing of NF‐κB2/p100 in T cells: evidence for the involvement of IKKα , 2001 .